After partnering with Depend last year following his bladder cancer surgery, Colorado head coach Deion Sanders brought his story to life in his first commercial for the company.

An aggressive bladder cancer diagnosis made 2025 one of the toughest years of Deion Sanders’ life. Coach Prime underwent a ...

Pfizer (NYSE:PFE) and Astellas Pharma reported positive pivotal Phase 3 results for PADCEV plus Keytruda in muscle invasive bladder cancer. The EV-304 (KEYNOTE-B15) trial showed a substantial ...

Aura Biosciences (NASDAQ:AURA) highlighted progress across its ocular oncology pipeline and provided updates on a parallel effort in bladder cancer during a fireside chat at TD Cowen’s 46th Annual ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...

UroGen Pharma's ZUSDURI is positioned for accelerated adoption following a permanent J-Code in 2026. Read more on URGN stock and why it is a Buy.

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

Dr. Pooja Ghatalia presents findings from RETAIN-2, a single-arm phase 2 non-randomized trial evaluating a ...

Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...

USA: A recent systematic review and meta-analysis published in Diabetes Research and Clinical Practice has unveiled compelling evidence that type 1 diabetes may be a significant and ...

Bladder cancer affects over 52,000 men and women in the United States on an annual basis, and more than 12,000 people die each year from this disease. It is the fourth most common cancer in men in ...